title: Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review.
abstract: The objective of the study was to review the literature reporting visual disturbance (VD)following sclerotherapy for varicose veins. Underlying mechanisms will be discussed. A literature search of the databases Medline and Google Scholar was performed. Original articles including randomized trials, case series and case reports reporting VD in humans following sclerotherapy for varicose veins were included. Additional references were also obtained if they had been referenced in related publications. The search yielded 4948 results of which 25 reports were found to meet the inclusion criteria. In larger series with at least 500 included patients the prevalence of VD following sclerotherapy ranges from 0.09% to 2%. In most reports foam sclerotherapy was associated with VD (19); exclusive use of liquid sclerosant was reported in two cases, some reports included foam and liquid sclerosant (4). There were no persistent visual disorders reported. VD occurred with polidocanol and sodium tetradecyl sulphate in different concentrations (0.25–3%). Various forms of foam preparation including various ways of foam production and the liquid –air ratio (1 or 2 parts of liquid mixed with 3, 4 or 5 parts of air) were reported in association with the occurrence of VD. VDs following sclerotherapy for varicose veins are rare and all reported events were transient. Bubble embolism or any kind of embolism seems unlikely to be the only underlying mechanism. A systemic inflammatory response following sclerotherapy has been suggested. Further research to clarify the mechanism of action of sclerosants is required.
authors.affiliation: Academic Section of Vascular Surgery Imperial College School of Medicine Charing Cross Hospital, London, UK.
authors.forename: T
authors.initials: T
authors.lastname: Willenberg
authors.forename: P C
authors.initials: PC
authors.lastname: Smith
authors.forename: A
authors.initials: A
authors.lastname: Shepherd
authors.forename: A H
authors.initials: AH
authors.lastname: Davies
mesh_terms: D004617:Embolism / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D006801:Humans; D016239:MEDLINE; D008297:Male; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D012597:Sclerosing Solutions / Q000009:adverse effects* / Q000627:therapeutic use; D015911:Sclerotherapy / Q000009:adverse effects* / Q000379:methods; D012981:Sodium Tetradecyl Sulfate / Q000009:adverse effects* / Q000627:therapeutic use; D013684:Telangiectasis / Q000453:epidemiology / Q000628:therapy*; D014648:Varicose Veins / Q000453:epidemiology / Q000628:therapy*; D014786:Vision Disorders / Q000139:chemically induced* / Q000453:epidemiology
chemical_list: D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols; D012981:Sodium Tetradecyl Sulfate